TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Turn Therapeutics Inc ( (TTRX) ) has issued an update.
On November 11, 2025, Turn Therapeutics announced that its GX-03 technology was recognized by Patient Care Online Magazine as one of the ‘Five Novel Mechanisms Reshaping Atopic Dermatitis Treatment.’ This recognition highlights the company’s innovative approach in dermatology, particularly with its topical IL36/IL31 inhibitor, which targets key inflammatory pathways in eczema and psoriasis. The announcement underscores Turn Therapeutics’ commitment to advancing its proprietary therapeutics pipeline, with plans to release topline data from its severe eczema program in early 2026.
More about Turn Therapeutics Inc
Turn Therapeutics is a biotechnology company focused on developing and commercializing products for dermatology, wound care, and infectious diseases. The company has received FDA clearances for its proprietary formulations and is advancing clinical programs in eczema and onychomycosis. Additionally, Turn is involved in global health initiatives aimed at thermostable vaccine delivery for underserved areas.
Average Trading Volume: 994,218
Find detailed analytics on TTRX stock on TipRanks’ Stock Analysis page.